Axsome Therapeutics vs Vanda Pharmaceuticals
AXSM and VNDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXSM and VNDA compare
Axsome Therapeutics is the larger company, worth 31 times as much as Vanda Pharmaceuticals ($7.1B against $230M).
Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 8.1% for Vanda Pharmaceuticals).
Axsome Therapeutics keeps more of each dollar of sales as profit, with a net margin of −24.7% compared with −120% at Vanda Pharmaceuticals.
Vanda Pharmaceuticals scores higher on the StockData Score (10 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXSM | VNDA |
|---|---|---|
| Size and price | ||
| Market cap | $7.1B | $230M |
| Share price | $135.95 | $3.81 |
| Change, 1 year | −2.7% | −12.4% |
| Change, 5 years | 268% | −77.0% |
| Beta (5Y) | 0.87 | 0.78 |
| Employees | 500 | 533 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.2× | 1.0× (better) |
| P/B | 85.5× | 1.2× (better) |
| FCF yield | −1.0% (better) | −60.8% |
| Fair value | – | $8.53 |
| Margin of safety | – | 55.3% |
| Growth | ||
| Revenue growth (TTM) | 56.9% (better) | 8.1% |
| Revenue growth, 5Y average | – | −2.7% |
| Profitability | ||
| Gross margin | 93.2% | 93.6% (better) |
| Operating margin | −24.0% (better) | −77.6% |
| Net margin | −24.7% (better) | −120% |
| FCF margin | −9.3% (better) | −61.0% |
| Return on equity | −245% | −82.5% (better) |
| Return on invested capital | – | −52.6% |
| Financial health | ||
| Debt / equity | 2.26 (better) | 0.00 |
| Current ratio | 1.43 | 1.54 (better) |
| Altman Z-score | 4.21 (better) | −1.85 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.50% | – |
| Shareholder yield | −0.50% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 73.8% | 82.2% |
| Held by insiders | 15.2% | 9.2% |
| Insider net buying, 12 months | −$113M | −$2.8M (better) |
| Short interest, % of float | 7.3% | 13.9% |
Go deeper
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
- VNDA stock overview
- VNDA income statement
- VNDA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.